The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona

Digestive and Liver Disease

Volumn 48, Issue 11, 2016, Pages 1283-1289

  Van Laethem, J L ^a   Carneiro, F ^b   Ducreux, M ^c   Messman, H ^d   Lordick, F ^e   Ilson, D H ^f   Allum, W H ^g   Haustermans, K ^h   Lepage, C ⁱ   Matysiak Budnik, T ^j   Cats, A ^k   Schmiegel, W ^l   Cervantes, A ^m   Van Cutsem, E ^h   Rougier, Ph ⁿ   Seufferlein, Th ^o  

^a ERASME HOSPITAL   (Belgium)

^b University of Porto   (Portugal)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Department of Trauma and Reconstructive Surgery   (Germany)

^e University Cancer Center Leipzig (UCCL)   (Germany)

^f Memorial Sloan Kettering Memorial Hospital   (United States)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k Netherland Kanker Institute   (Netherlands)

^l ST JOSEF HOSPITAL   (Germany)

^m UNIVERSITY OF VALENCIA   (Spain)

ⁿ HÔTEL DIEU   (France)

^o UNIVERSITY OF ULM   (Germany)

more..

Author keywords

Endoscopic treatment; Gastro oesophageal junction cancer; Multimodal therapy

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PROTEIN TYROSINE KINASE; RAMUCIRUMAB; TRASTUZUMAB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CHROMOENDOSCOPY; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENDOSCOPIC SURGERY; ENDOSCOPIC THERAPY; ESOPHAGUS TUMOR; EUROPE; EVIDENCE BASED MEDICINE; GASTROESOPHAGEAL JUNCTION; GASTROESOPHAGEAL JUNCTION TUMOR; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TUMOR; HUMAN; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; NUTRITIONAL SUPPORT; PARENTERAL NUTRITION; PRIORITY JOURNAL; TOTAL STOMACH RESECTION; TREATMENT DURATION; TUMOR BIOPSY; ADENOCARCINOMA; DRUG THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOSTOMY; GASTRECTOMY; MEDICAL SOCIETY; ONCOLOGY; ORGANIZATION; PALLIATIVE THERAPY; PATHOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPAIN; STOMACH NEOPLASMS; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; CONGRESSES AS TOPIC; DRUG THERAPY; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; ESOPHAGOSTOMY; EVIDENCE-BASED MEDICINE; GASTRECTOMY; HUMANS; MEDICAL ONCOLOGY; NEOPLASM STAGING; NUTRITIONAL SUPPORT; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES, MEDICAL; SPAIN; STOMACH NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84992482340     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.08.112     Document Type: Article

References (61)

1. [1] Steyerberg, E.W., Neville, B., Weeks, J.C., et al. Referral patterns, treatment choices and outcomes in locoregionalesophageal cancers: a population-based analysis of elderly patients. Journal of Clinical Oncology 25 (2007), 2389–2396.
2. [2] Chapelle, N., Manfredi, S., Lepage, C., et al. Trends in gastric cancer incidence: a period and birth cohort analysis in a well-defined French population. Gastric Cancer, 19, 2016, 682.
3. [3] Lepage, C., Sant, M., Verdacchia, A., et al. EUROCARE working group: operative mortality after gastric cancer resection and long-term survival differences across Europe. British Journal of Surgery 97 (2010), 235–239.
4. [4] Allum, W.H., Blazeby, J.M., Griffin, S.M., et al. Guidelines for the management of oesophageal and gastric cancer. Gut 60 (2011), 1449–1472.
5. [5] Bennett, C., Vakil, N., Bergman, J., et al. Consensus statements for management of Barrett's dysplasia and early stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 143 (2012), 336–346.
6. [6] Waddell, T., Verheij, M., Allum, W., Cunningham, D., Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 24 (2013), vi57–63.
7. [7] Bouvier, A.M., Sant, M., Verdacchia, A., et al. What reasons lie behind long-term survival differences for gastric cancer within Europe?. European Journal of Cancer 46 (2010), 1086–1092.
8. [8] Odze, R.D., Fléjou, J.-F., Boffetta, P., et al. Adenocarcinoma of the oesophagogastric junction. Bosman, F.T., Carneiro, F., Hruban, R.H., Theise, N.D., (eds.) WHO classification of tumours of the digestive system, 4th ed., 2010, IARC Press, Lyon.
9. [9] International Union against Cancer, Sobin, L.H., Gospodarowicz, M.K., Wittekind, C., (eds.) TNM classification of malignant tumours, 7th ed., 2009, Wiley-Blackwell, Oxford, UK.
10. [10] Siewert, J.R., Stein, H.J., Classification of adenocarcinoma of the oesophago-gastric junction. British Journal of Surgery 85 (1988), 1457–1459.
11. [11] Van Cutsem, E., Bang, Y.J., Feng-Yi, F., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18 (2015), 476–484.
12. [12] Durães, C., Almeida, G.M., Seruca, R., et al. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy. Virchows Archiv 464 (2014), 367–378.
13. [13] Tanner, M., Hollmen, M., Junttila, T.T., et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of Oncology 16 (2015), 273–278.
14. [14] Bar-Sela, G., Hershkovitz, D., Haim, N., et al. The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. Oncology Letters 5 (2013), 559–563.
15. [15] Gordon, M.A., Gundacker, H.M., Benedetti, J., et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Annals of Oncology 24 (2013), 1754–1761.
16. [16] Grabsch, H., Sivakumar, S., Gray, S., Gabbert, H.E., Muller, W., HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series. Cellular Oncology 32 (2010), 57–65.
17. [17] Okines, A.F., Thompson, L.C., Cunningham, D., et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Annals of Oncology 24 (2013), 1253–1261.
18. [18] Moehler, M., Al-Batran, S.E., Andus, T., et al. German S3-guideline “diagnosis and treatment of esophagogastric cancer”. Zeitschrift fur Gastroenterologie 49 (2011), 461–531.
19. [19] Koop, H., Fuchs, K.H., Labenz, J., et al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013. Zeitschrift fur Gastroenterologie 52 (2014), 1299–1346.
20. [20] Bennett, C., Vakil, N., Bergman, J., et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 143 (2012), 336–346.
21. [21] Moehler, M., Baltin, C.T., Ebert, M., et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 18 (2015), 550–563.
22. [22] Phoa, K.N., van Vilsteren, F.G., Weusten, B.L., et al. Radiofrequency ablation vs. endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 311 (2014), 1209–1217.
23. [23] Pech, O., May, A., Manner, H., Behrens, A., et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 146 (2014), 652–660.
24. [24] Probst, A., Aust, D., Märkl, B., et al. Early esophageal cancer in Europe: endoscopic treatment by endoscopic submucosal dissection. Endoscopy 47 (2015), 113–121.
25. [25] Shaheen, N.J., Sharma, P., Overholt, B.F., et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. New England Journal of Medicine 360 (2009), 2277–2288.
26. [26] Probst, A., Golger, D., Arnholdt, H., et al. Endoscopic submucosal dissection of early cancers, flat adenomas, and submucosal tumors in the gastrointestinal tract. Clinical Gastroenterology and Hepatology 7 (2009), 149–155.
27. [27] Probst, A., Golger, D., Anthuber, M., et al. Endoscopic submucosal dissection in large sessile lesions of the rectosigmoid: learning curve in a European center. Endoscopy 44 (2012), 660–667.
28. [28] Hulscher, J.B., van Sandick, J.W., de Boer, A.G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinomas of the esophagus. New England Journal of Medicine 21 (2002), 1662–1669.
29. [29] Omloo, J.M., Lagarde, S.M., Hulscher, J.B., et al. Extended transthoracic resection compared with limited transhiatal resection for adeocarcinoma of the mid/distal esophagus: five year survival of a randomised clinical trial. Annals of Surgery 6 (2007), 992–1000.
30. [30] Messager, M., de Steur, W.O., van Sandick, J.W., et al. Variations among 5 European countries for curative treatment of resectable oesophageal and gastric cancer: a survey from the EURECCA Upper GI Group. European Journal of Surgical Oncology 42 (2016), 116–122.
31. [31] Biere, S.S., Maas, K.W., Bonavina, L., et al. Traditional invasive vs minimally invasive esophagectomy: a multicentre randomised trial (TIME-trial). BMC Surgery 1 (2011), 2–8.
32. [32] Briez, N., Piessen, G., Torres, F., et al. Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. British Journal of Surgery 99 (2012), 1547–1553.
33. [33] Sjoquist, K.M., Burmeister, B.H., Smithers, B.M., et al. Survival after neoadjuvant chemotherapy or chemoradiationfor resectable oesophageal carcinoma: an updated meta-analysis Group. The Lancet Oncology 12 (2011), 681–692.
34. [34] Lutz, M.P., Zalcberg, J.R., Ducreux, M., et al. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer—differential treatment strategies for subtypes of early gastroesophageal cancer. European Journal of Cancer 48 (2012), 2941–2953.
35. [35] Cunningham, D., Allum, W.H., Stenning, S.P., et al. perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 355 (2006), 11–12.
36. [36] Ychou, M., Boige, V., Pignon, J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology 29 (2011), 1715–1717.
37. [37] Allum Stenning, S.P., Bancewicz, J., et al. Long term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology 27 (2009), 5062–5067.
38. [38] van Hagen, P., Hulshof, M.C., van Lansschot, J.J.B., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine 366 (2012), 2074–2084.
39. [39] Shapiro, J., van lanschot, J.J.B., Hulshof, M.C., et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long term results of a randomised controlled trial. Lancet Oncology 16 (2015), 1090–1098.
40. [40] Alderson, D., Langley, R., Nankivell, M., et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma/results from the UK medical Research council randomised OEO5 trial. Journal of Clinical Oncology, 33, 2015 (suppl, abs 4002).
41. [41] Cunningham, D., Smyth, E., Stenning, S., et al. Peri-operative chemotherapy +/− bevacizumab for resectable gastro-oesophageal adenocarcinoma: results from the UK Medical Research Council randomised ST03 trial. ESMO-ECCO, 2015 (abs 2201).
42. [42] Lordick, F., Ott, K., Krause, B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncology 8 (2007), 797–805.
43. [43] Downey, R.J., Ilson, D.H., PET-guided induction chemotherapy. Lancet Oncology 8 (2007), 754–755.
44. [44] Lordick, F., Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results in Cancer Research 196 (2012), 201–211.
45. [45] Paoletti, X., Oba, K., Burzykowski, T., et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303 (2010), 1729–1737.
46. [46] Won, E., Ilson, D., Management of localized esophageal cancer in the older patients. The Oncologist 19 (2014), 367–374.
47. [47] Al Batran, S.E., Hartmann, J.T., Probst, S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology 26 (2008), 1435–1444.
48. [48] Webb, A., Cunningham, D., Scarffe, J.H., et al. Randomized trial comparing epirubicin,cisplatin and fluorouracil vs fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology 15 (1997), 261–267.
49. [49] Van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., et al. Phase III study of docetaxel and cisplatinplus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advance gastric cancer: a report of the V-325 study group. Journal of Clinical Oncology 24 (2006), 4991–4997.
50. [50] Cunningham, D., Starling, N., Rao, S., et al. Capecitabine and oxaliplatine for advanced esophagogastric cancer. New England Journal of Medicine 358 (2008), 36–46.
51. [51] Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or GEJ cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 376 (2010), 687–697.
52. [52] Guimbaud, R., Louvet, C., Ries, P., et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma. Journal of Clinical Oncology 32 (2014), 3520–3526.
53. [53] Fuchs, C.S., Tomasek, J., Yong, C.J., et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 383 (2014), 31–954.
54. [54] Wilke, H., Muro, K., Van Cutsem, E., et al. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology 15 (2014), 1224–1235.
55. [55] Li, J., Qin, S., Xu, J., et al. Randomized, double blind, placebo-controlled phase III trial of apatinib in patients with chemo-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. Journal of Clinical Oncology 34 (2016), 1448–1454.
56. [56] Dahle-Smith, A., Petty, R.D., Biomarkers and novel agents in esophago-gastric cancer: are we making progress. Expert Review of Anticancer Therapy 15 (2015), 1103–1119.
57. [57] Cancer genome Atlas Research Network: comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202–9.
58. [58] Gronnier, C., Meunier, B., Pezet, D., et al. MIRO trial. JFHOD, 2015, C081.
59. [59] Messager, M., Pasquer, A., Duhamel, A., et al. Laparoscopic gastric mobilization reduces postoperative mortality after esophageal cancer surgery: a French Nationwide Study. Annals of Surgery 262:5 (2015), 817–822.
60. [60] Verheij, M., Jansen, E.P., Cats, A., et al. A multicentre randomized phase III trial of neoadjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: first results from the CRITICS study. Journal of Clinical Oncology(Suppl), 2016 abs 4000.
61. [61] Muro, K., Chung, H.C., Shankaran, V., et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncology 17 (2016), 717–726.